139 related articles for article (PubMed ID: 36417840)
21. Comparative Outcomes in Patients With Small- and Large-Cell Neuroendocrine Carcinoma (NEC) and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm (MiNEN) of the Stomach.
Choi NY; Kim BS; Oh ST; Yook JH; Kim BS
Am Surg; 2021 Apr; 87(4):631-637. PubMed ID: 33142079
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological characteristics of gastric neuroendocrine neoplasms: A comprehensive analysis.
Zi M; Ma Y; Chen J; Pang C; Li X; Yuan L; Liu Z; Yu P
Cancer Med; 2024 Feb; 13(4):e7011. PubMed ID: 38457192
[TBL] [Abstract][Full Text] [Related]
23. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
[TBL] [Abstract][Full Text] [Related]
24. Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.
Ooki A; Osumi H; Fukuda K; Yamaguchi K
Cancer Metastasis Rev; 2023 Sep; 42(3):1021-1054. PubMed ID: 37422534
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants.
Matsui K; Jin XM; Kitagawa M; Miwa A
Arch Pathol Lab Med; 1998 Nov; 122(11):1010-7. PubMed ID: 9822131
[TBL] [Abstract][Full Text] [Related]
26. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
[No Abstract] [Full Text] [Related]
27. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas.
Dasari A; Shen C; Devabhaktuni A; Nighot R; Sorbye H
Oncologist; 2022 Apr; 27(4):299-306. PubMed ID: 35380711
[TBL] [Abstract][Full Text] [Related]
28. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
[TBL] [Abstract][Full Text] [Related]
29. Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.
Carlinfante G; Baccarini P; Berretti D; Cassetti T; Cavina M; Conigliaro R; De Pellegrin A; Di Tommaso L; Fabbri C; Fornelli A; Frasoldati A; Gardini G; Losi L; Maccio L; Manta R; Pagano N; Sassatelli R; Serra S; Camellini L
Virchows Arch; 2014 Jul; 465(1):49-55. PubMed ID: 24807732
[TBL] [Abstract][Full Text] [Related]
30. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
31. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract][Full Text] [Related]
32. Differences in clinicopathology and prognosis between gastroesophageal junctional and gastric non-cardiac neuroendocrine carcinomas: a retrospective comparison study of consecutive 56 cases from a single institution in China.
Cheng Y; Zhang X; Zhou X; Xu K; Lin M; Huang Q
Am J Cancer Res; 2022; 12(10):4737-4750. PubMed ID: 36381336
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients.
Xie JW; Lu J; Wang JB; Lin JX; Chen QY; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Zheng CH; Li P; Huang CM
BMC Cancer; 2018 Oct; 18(1):1021. PubMed ID: 30348122
[TBL] [Abstract][Full Text] [Related]
34. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
[TBL] [Abstract][Full Text] [Related]
35. Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study.
Chen J; Wang A; Ji K; Bu Z; Ji J
BMC Cancer; 2020 Aug; 20(1):777. PubMed ID: 32811471
[TBL] [Abstract][Full Text] [Related]
36. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?
Hijioka S; Hosoda W; Mizuno N; Hara K; Imaoka H; Bhatia V; Mekky MA; Tajika M; Tanaka T; Ishihara M; Yogi T; Tsutumi H; Fujiyoshi T; Sato T; Hieda N; Yoshida T; Okuno N; Shimizu Y; Yatabe Y; Niwa Y; Yamao K
J Gastroenterol; 2015 May; 50(5):564-72. PubMed ID: 25142799
[TBL] [Abstract][Full Text] [Related]
37. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT.
Park HJ; Kim HJ; Kim KW; Kim SY; Choi SH; You MW; Hwang HS; Hong SM
Eur Radiol; 2020 Sep; 30(9):4772-4782. PubMed ID: 32346794
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms.
Gao C; Fan Z; Yang J; Shi M; Li Y; Zhan H
Pancreatology; 2023 Mar; 23(2):204-212. PubMed ID: 36710224
[TBL] [Abstract][Full Text] [Related]
39. Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual.
Deng BY; Yang M; Wen JY; Hou SZ; Chen Y; Tian BL; Liu XB; Zhang Y
Medicine (Baltimore); 2020 Jan; 99(3):e18736. PubMed ID: 32011453
[TBL] [Abstract][Full Text] [Related]
40. Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia.
Abdelmalak R; Lythgoe MP; Evans J; Flynn M; Waters J; Webb A; Pinato DJ; Sharma R
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
